IN2014CN04676A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04676A IN2014CN04676A IN4676CHN2014A IN2014CN04676A IN 2014CN04676 A IN2014CN04676 A IN 2014CN04676A IN 4676CHN2014 A IN4676CHN2014 A IN 4676CHN2014A IN 2014CN04676 A IN2014CN04676 A IN 2014CN04676A
- Authority
- IN
- India
- Prior art keywords
- general formula
- compounds
- prodrugs
- solvates
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1122139.7A GB2497806A (en) | 2011-12-21 | 2011-12-21 | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| GB201217290A GB201217290D0 (en) | 2012-09-27 | 2012-09-27 | Compounds |
| PCT/GB2012/053217 WO2013093484A1 (fr) | 2011-12-21 | 2012-12-20 | Dérivés de pyridinone et de pyrimidinone comme inhibiteurs du facteur xia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04676A true IN2014CN04676A (fr) | 2015-09-18 |
Family
ID=47553259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4676CHN2014 IN2014CN04676A (fr) | 2011-12-21 | 2012-12-20 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9732085B2 (fr) |
| EP (2) | EP3290413B9 (fr) |
| JP (2) | JP6137193B2 (fr) |
| KR (1) | KR102011534B1 (fr) |
| CN (1) | CN104136431B (fr) |
| AU (1) | AU2012356374B2 (fr) |
| BR (1) | BR112014015669B1 (fr) |
| CA (1) | CA2859604C (fr) |
| DK (1) | DK2794597T3 (fr) |
| ES (2) | ES2765891T3 (fr) |
| HK (1) | HK1198386A1 (fr) |
| HU (1) | HUE036010T2 (fr) |
| IL (1) | IL233154A (fr) |
| IN (1) | IN2014CN04676A (fr) |
| MX (1) | MX351471B (fr) |
| NO (1) | NO2794597T3 (fr) |
| PH (1) | PH12014501365A1 (fr) |
| PL (1) | PL2794597T3 (fr) |
| PT (1) | PT2794597T (fr) |
| RU (1) | RU2630677C2 (fr) |
| SG (1) | SG11201403402VA (fr) |
| TW (1) | TWI613199B (fr) |
| WO (1) | WO2013093484A1 (fr) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2534152B1 (fr) | 2010-02-11 | 2018-05-02 | Bristol-Myers Squibb Company | Macrocycles comme inhibiteurs du factor xia |
| US9062061B2 (en) * | 2011-07-13 | 2015-06-23 | Santen Pharmaceutical Co., Ltd. | Compound having PARP inhibitory activity |
| JP6033318B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| EP2899183B1 (fr) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Composés de tétrahydroisiquinoline substitués en tant qu'inhibiteurs du facteur Xia |
| ES2625256T3 (es) | 2011-10-14 | 2017-07-19 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA |
| EP3290413B9 (fr) * | 2011-12-21 | 2020-04-29 | ONO Pharmaceutical Co., Ltd. | Dérivés de pyridinone et de pyrimidinone en tant qu'inhibiteurs du facteur xia |
| WO2013096637A1 (fr) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations de ceux-ci |
| CA2881566A1 (fr) | 2012-07-19 | 2014-01-23 | Yohei Ikuma | Derive de 1-(cycloalkyl-carbonyl)proline |
| AU2013296258A1 (en) | 2012-08-03 | 2015-03-19 | Bristol-Myers Squibb Company | Dihydropyridone P1 as factor XIa inhibitors |
| TW201410667A (zh) | 2012-08-03 | 2014-03-16 | 必治妥美雅史谷比公司 | 二氫吡啶酮ｐ１作爲凝血因子ｘｉａ抑制劑 |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014059202A1 (fr) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Composés de tétrahydroisoquinoléine substitués par guanidine comme inhibiteurs du facteur xia |
| WO2014059203A1 (fr) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Formes cristallines d'un inhibiteur de facteur xia |
| EP2978751B1 (fr) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tétrahydroisoquinolines comprenant des azoles substitués en tant qu'inhibiteurs du facteur xia |
| US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| CA2918814C (fr) * | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Derives de l'oxopyridine substitues et utilisation desdits derives comme facteur xia/plasma |
| CA2928867A1 (fr) * | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Derives d'oxopyridine substituee |
| NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
| SG11201606209PA (en) | 2014-01-31 | 2016-08-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| US9676723B2 (en) | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
| EP3104703B1 (fr) | 2014-02-11 | 2020-11-18 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| EP3138839B1 (fr) * | 2014-02-14 | 2020-10-28 | Sichuan Haisco Pharmaceutical Co., Ltd. | Dérivé de pyrimidone ou de pyridone, procédé de préparation associé et application correspondante |
| WO2015164308A1 (fr) | 2014-04-22 | 2015-10-29 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| CN105658641B (zh) * | 2014-07-25 | 2018-04-17 | 江苏恒瑞医药股份有限公司 | 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2016015593A1 (fr) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｆｘｉａ阻害剤であるジアミドマクロ環 |
| CN104311537B (zh) * | 2014-09-19 | 2016-08-24 | 广东东阳光药业有限公司 | 含有嘧啶酮乙酰基取代基吡唑类化合物及其组合物及用途 |
| WO2016046164A1 (fr) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| EP3197896B1 (fr) * | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (fr) * | 2014-10-01 | 2018-10-20 | ||
| AU2015362422B2 (en) * | 2014-12-10 | 2019-11-14 | Ono Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| RU2649141C2 (ru) * | 2015-04-20 | 2018-03-30 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| RU2653511C2 (ru) * | 2015-07-29 | 2018-05-10 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 4-метил-n-2,4-диметилфенил-6-(3-фторфенил)-2-тиоксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий анальгетическое действие |
| JP6785838B2 (ja) | 2015-08-05 | 2020-11-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 新規な置換グリシン誘導のｆｘｉａ阻害剤 |
| CN106496249B (zh) * | 2015-09-07 | 2019-12-13 | 江苏恒瑞医药股份有限公司 | 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用 |
| EP3368036B1 (fr) | 2015-10-29 | 2022-07-20 | Merck Sharp & Dohme LLC | Dérivés macrocycliques de pyridine n-oxyde en tant qu'inhibiteurs du facteur xia |
| WO2017074833A1 (fr) | 2015-10-29 | 2017-05-04 | Merck Sharp & Dohme Corp. | Dérivé spirocarbamate macrocyclique comme inhibiteurs du facteur xia, compositions pharmaceutiquement acceptables et leur utilisation |
| JP6992284B2 (ja) * | 2016-06-06 | 2022-01-13 | 小野薬品工業株式会社 | ジヒドロインドリジノン誘導体を含有する医薬組成物 |
| US10143681B2 (en) | 2016-08-22 | 2018-12-04 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
| EP3305538A1 (fr) | 2016-10-07 | 2018-04-11 | Mitsubishi HiTec Paper Europe GmbH | Matériel d'enregistrement sensible à la chaleur |
| US10882348B2 (en) | 2016-10-07 | 2021-01-05 | Mitsubishi Hitec Paper Europe Gmbh | Heat-sensitive recording material |
| CN106950319B (zh) * | 2017-04-20 | 2019-08-30 | 西安科技大学 | 一种检测特鲁曲班光学异构体含量的方法 |
| CN109507345B (zh) * | 2017-09-15 | 2022-08-05 | 万特制药(海南)有限公司 | 重酒石酸卡巴拉汀中间体及其杂质的分离测定方法 |
| TWI802654B (zh) * | 2018-02-27 | 2023-05-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種酮基吡啶醯胺類衍生物的晶型及其製備方法 |
| KR20210028232A (ko) | 2018-07-02 | 2021-03-11 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 옥시피리딘 아미드 유도체의 결정 형태 및 이를 위한 제조 방법 |
| TWI825144B (zh) * | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
| CN111727186B (zh) * | 2018-11-11 | 2022-11-08 | 上海海雁医药科技有限公司 | 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途 |
| WO2020111268A1 (fr) * | 2018-11-30 | 2020-06-04 | 小野薬品工業株式会社 | Nouveau cristal de (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tétrazole-1-yl)phényl]-2,3-dihydroindolizine-5(1h)-one |
| CN109836360B (zh) * | 2019-03-19 | 2021-08-13 | 南京恩泰医药科技有限公司 | 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物 |
| CN112028877B (zh) * | 2019-06-04 | 2021-11-26 | 江西济民可信集团有限公司 | 烷氧吡啶酮化合物及其制备方法和用途 |
| EP3998263A4 (fr) * | 2019-06-28 | 2023-09-06 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Composé tricyclique, son procédé de préparation et son utilisation |
| CN114206854B (zh) | 2019-09-27 | 2023-02-24 | 深圳信立泰药业股份有限公司 | FXIa抑制剂及其制备方法和医药用途 |
| CN112778277B (zh) * | 2019-11-11 | 2024-04-02 | 江西济民可信集团有限公司 | 环酮并吡啶酮联杂芳环化合物及其制备方法和用途 |
| JP2023534704A (ja) * | 2020-07-22 | 2023-08-10 | ヤンセン ファーマシューティカ エヌ．ベー． | 第ｘｉａ因子阻害剤として有用な化合物 |
| WO2023002984A1 (fr) * | 2021-07-20 | 2023-01-26 | 小野薬品工業株式会社 | Procédé de production d'un composé imidazolique |
| US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
| US20230097157A1 (en) * | 2021-07-22 | 2023-03-30 | Janssen Pharmaceutica Nv | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors |
| CN113735770B (zh) * | 2021-09-30 | 2023-06-06 | 四川大学 | 一种铑催化的4-苯基噁二唑酮与碳酸亚乙烯酯合成1-氨基异喹啉骨架的方法 |
| WO2023179624A1 (fr) * | 2022-03-21 | 2023-09-28 | 上海济煜医药科技有限公司 | Procédé de préparation d'un composé tricyclique et d'un intermédiaire de celui-ci |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0042675A1 (fr) | 1980-06-20 | 1981-12-30 | Norton Company | Procédé pour fixer une meule sur un arbre |
| EP0262696A3 (fr) | 1982-05-18 | 1988-07-20 | University Of Florida | Administration d'un médicament à action spécifique sur le cerveau |
| CA1241120A (fr) | 1985-10-01 | 1988-08-23 | Sami A. Aly | Recepteur de signaux bipolaires alternants |
| CA1334092C (fr) * | 1986-07-11 | 1995-01-24 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii |
| EP0407342A3 (en) * | 1989-07-06 | 1991-07-10 | Ciba-Geigy Ag | Pyrimidine derivatives |
| DE4221583A1 (de) * | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
| DE4407488A1 (de) * | 1994-03-07 | 1995-09-14 | Bayer Ag | Verwendung von Biphenyl- und Pyridylmethylpyridonen |
| ES2334990T3 (es) | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | Piridinonas sustituidas como moduladores de p38 map quinasa. |
| DE602004010206T2 (de) | 2003-08-13 | 2008-10-09 | Takeda Pharmaceutical Co. Ltd. | Dipeptidyl Peptidase Inhibitoren. |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| BRPI0518126A (pt) | 2004-10-15 | 2008-10-28 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição |
| KR20070086610A (ko) | 2004-11-24 | 2007-08-27 | 버텍스 파마슈티칼스 인코포레이티드 | 3-[2-(3-아실아미노-2-옥소-2ｈ-피리딘-1-일)-아세틸아미노]-4-옥소-펜탄산 유도체 및 카스파제 억제제로서의 이의용도 |
| AR056682A1 (es) | 2005-07-29 | 2007-10-17 | Kalypsys Inc | COMPUESTOS MULTICíCLICOS DERIVADOS DE LA SULFONAMIDA COMO INHIBIDORES DE LA HISTONA DESACETILASA Y COMPOSICIoN FARMACÉUTICA |
| CN101341129B (zh) * | 2005-12-14 | 2011-12-14 | 布里斯托尔-迈尔斯斯奎布公司 | 作为因子xia抑制剂的芳基丙酰胺，芳基丙烯酰胺，芳基丙炔酰胺，或芳基甲基脲类似物 |
| WO2007070826A1 (fr) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Analogues de l'arylpropionamide, de l'arylacrylamide, de l'arylpropynamide ou de l'arylmethyluree en tant qu'inhibiteurs du facteur xia |
| AU2007322608A1 (en) * | 2006-11-24 | 2008-05-29 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound and use thereof |
| ES2546815T3 (es) * | 2006-12-15 | 2015-09-28 | Bristol-Myers Squibb Company | Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa |
| US20100298372A1 (en) | 2007-12-11 | 2010-11-25 | Schering Corporation | Gamma secretase modulators |
| CN102026996B (zh) * | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| US8946426B2 (en) | 2009-02-06 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| EP2625170A1 (fr) * | 2010-10-07 | 2013-08-14 | Takeda Pharmaceutical Company Limited | Dérivés de 1,4-oxazépane |
| EP3290413B9 (fr) * | 2011-12-21 | 2020-04-29 | ONO Pharmaceutical Co., Ltd. | Dérivés de pyridinone et de pyrimidinone en tant qu'inhibiteurs du facteur xia |
-
2012
- 2012-12-20 EP EP17193874.9A patent/EP3290413B9/fr not_active Not-in-force
- 2012-12-20 CN CN201280070352.3A patent/CN104136431B/zh not_active Expired - Fee Related
- 2012-12-20 TW TW101148629A patent/TWI613199B/zh not_active IP Right Cessation
- 2012-12-20 WO PCT/GB2012/053217 patent/WO2013093484A1/fr active Application Filing
- 2012-12-20 KR KR1020147016952A patent/KR102011534B1/ko active IP Right Grant
- 2012-12-20 NO NO12813423A patent/NO2794597T3/no unknown
- 2012-12-20 ES ES17193874T patent/ES2765891T3/es active Active
- 2012-12-20 EP EP12813423.6A patent/EP2794597B1/fr active Active
- 2012-12-20 BR BR112014015669-7A patent/BR112014015669B1/pt not_active IP Right Cessation
- 2012-12-20 IN IN4676CHN2014 patent/IN2014CN04676A/en unknown
- 2012-12-20 AU AU2012356374A patent/AU2012356374B2/en not_active Ceased
- 2012-12-20 PT PT128134236T patent/PT2794597T/pt unknown
- 2012-12-20 JP JP2014548196A patent/JP6137193B2/ja active Active
- 2012-12-20 CA CA2859604A patent/CA2859604C/fr active Active
- 2012-12-20 PL PL12813423T patent/PL2794597T3/pl unknown
- 2012-12-20 ES ES12813423.6T patent/ES2655669T3/es active Active
- 2012-12-20 DK DK12813423.6T patent/DK2794597T3/en active
- 2012-12-20 RU RU2014129797A patent/RU2630677C2/ru active
- 2012-12-20 MX MX2014007269A patent/MX351471B/es active IP Right Grant
- 2012-12-20 HU HUE12813423A patent/HUE036010T2/hu unknown
- 2012-12-20 US US14/366,396 patent/US9732085B2/en active Active
- 2012-12-20 SG SG11201403402VA patent/SG11201403402VA/en unknown
-
2014
- 2014-06-16 IL IL233154A patent/IL233154A/en active IP Right Grant
- 2014-06-16 PH PH12014501365A patent/PH12014501365A1/en unknown
- 2014-11-25 HK HK14111900.0A patent/HK1198386A1/xx not_active IP Right Cessation
-
2017
- 2017-05-01 JP JP2017091408A patent/JP6447660B2/ja not_active Expired - Fee Related
- 2017-07-07 US US15/644,655 patent/US10717738B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04676A (fr) | ||
| PH12017502141A1 (en) | Compounds and their methods of use | |
| PH12014502573A1 (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| MX356368B (es) | Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| PH12015500064A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| IN2014KN00769A (fr) | ||
| MX355728B (es) | Inhibidores de cinasas. | |
| IN2014DN10670A (fr) | ||
| IN2014CN02805A (fr) | ||
| IN2014CN02806A (fr) | ||
| MX2013009873A (es) | Inhibidores triciclicos de cinasas. | |
| MX352975B (es) | Piridina y derivados de pirazina. | |
| MX364602B (es) | Inhibidores selectivos de glicosidasa y usos de los mismos. | |
| IN2015DN00598A (fr) | ||
| UA111744C2 (uk) | ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| GB201209587D0 (en) | Therapeutic compounds | |
| IN2014MN01465A (fr) | ||
| MX362879B (es) | Usos novedosos. | |
| IN2014MN01486A (fr) | ||
| EA201391586A1 (ru) | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ | |
| IN2014DN08443A (fr) | ||
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |